A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma

Current Oncology

Volumn 19, Issue 3, 2012, Pages 160-168

  van der Jagt, R ^a   Laneuville, P ^b   MacDonald, D ^c   Stewart, D ^d   Christofides, A ^e   Sehn, L H ^f  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e New Evidence   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Bendamustine; Chronic lymphocytic leukemia; Follicular lymphoma; Non Hodgkin lymphoma

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; LENALIDOMIDE; MITOXANTRONE; OBINUTUZUMAB; OFATUMUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE;

ALOPECIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANADA; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; INFECTIOUS COMPLICATION; LEUKOPENIA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT RESPONSE; VOMITING;

EID: 84930485108     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1064     Document Type: Article

References (42)

1. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase ii trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559-66.
2. Garnock-Jones KP. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Drugs 2010;70:1703-18.
3. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-17.
4. Tageja N. Bendamustine: safety and efficacy in the management of indolent non-Hodgkins lymphoma. Clin Med Insights Oncol 2011;5:145-56.
5. Leoni LM. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol 2011;48(suppl 1):S4-11.
6. Cheson BD, Wendtner CM, Pieper A, et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010;10:21-7.
7. Cephalon Inc. Product monograph: Treanda (bendamustine hydrochloride). Frazer, PA: Cephalon; 2010.
8. Seftel MD, Demers AA, Banerji V, et al. High incidence of chronic lymphocytic leukemia (cll) diagnosed by immunophenotyping: a population-based Canadian cohort. Leuk Res 2009;33:1463-8.
9. Shanafelt TD, Kay NE. Comprehensive management of the cll patient: a holistic approach. Hematology Am Soc Hematol Educ Program 2007;:324-31.
10. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase iii randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-84.
11. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine in the treatment of chronic lymphocytic leukemia-consistent superiority over chlorambucil in elderly patients and across clinically defined risk groups [abstract 2367]. Blood 2009;114
12. Malin J, Kongnakorn T, Sterchele J, Salvador C, Getsios D, Mwamburi M. Cost-effectiveness analysis of bendamustine compared to alemtuzumab and chlorambucil for chronic lymphocytic leukemia in a treatment-naïve population. Poster presentation at the International Society for Pharmacoeconomics and Outcomes (ispor) 15th Annual International Meeting; Atlanta, GA, U.S.A.; May 15-19, 2010. [Available online at: http://unitedbiosource.com/pdfs/2010%20posters/ISPOR/malin_bendamustine.pdf; cited April 20, 2012]
13. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukemia [abstract 2449]. Blood 2010;116
14. Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (br) in first-line therapy of advanced cll: a multicenter phase ii trial of the German cll Study Group (gcllsg) [abstract 205]. Blood 2009;114
15. Pennese E, Di Renzo N. Rituximab plus bendamustine (rb) regimen in elderly previously untreated patients with indolent, non follicular non Hodgkin lymphoma: preliminary data of a single center study [abstract 1440]. Haematologica 2011;96(suppl 2):574.
16. Niederle N, Balleisen L, Heit W, et al. Bendamustine vs fludarabine as second-line treatment for patients with chronic lymphocytic leukemia-first interim results of a randomized study [abstract]. Ann Oncol 2008;19:379.
17. Rigacci L, Puccini B, Orciuolo E, et al. Safety and efficacy of bendamustine with or without rituximab for the treatment of heavily pretreated cll and lymphoma patients. A multicenter retrospective study [abstract 1662]. Blood 2009;114
18. Egle A, Melchardt T, Weiss L, Steurer M, Greil R. The bendalem cll 6 agmt study-bendamustine combined with alemtuzumab in relapsed/refractory chronic lymphocytic leukemia (cll): results of a planned interim analysis [abstract 4633]. Blood 2010;116
19. Sanchez-Gonzalez B, Penalver FJ, Guillen H, et al. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia: Spanish registry [abstract 3698]. Blood 2009;114
20. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52.
21. Czuczman MS. Controversies in follicular lymphoma: "who, what, when, where, and why?" (Not necessarily in that order!). Hematology Am Soc Hematol Educ Program 2006;:303-10.
22. BC Cancer Agency (bcca). BC Cancer Agency > Health Professionals Info > Cancer Management Guidelines > Lymphoma (Including Chronic Leukemia and Myeloma) [Web resource]. Vancouver, BC: bcca; n.d. [Available online at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Lymphoma/default.htm; cited December 10, 2011]
23. Alberta Health Services. Lymphoma. Clinical Practice Guideline LYHE-002. Edmonton, AB: Alberta Health Services; November 2009.
24. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (prima): a phase 3, randomised controlled trial. Lancet 2011;377:42-51.
25. Morschhauser F, Seymour J, Feugier P, et al. Impact of induction chemotherapy regimen on response, safety and outcome in the prima Study [abstract 002]. Ann Oncol 2011;22:iv89.
26. Federico M. r-cvp vs r-chop vs r-fm for the initial treatment of patients with advanced stage follicular lymphoma-preliminary results of foll05 iil trial [abstract 35]. Ann Oncol 2011;2(suppl 4):1839.
27. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (bop) versus cyclophosphamide, vincristine and prednisone (cop) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase iii trial (osho#19). J Cancer Res Clin Oncol 2006;132:105-12.
28. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and cr rate when compared to chop plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase iii study of the stil (Study Group Indolent Lymphomas, Germany) [abstract 405]. Blood 2009;114
29. Fowler NH, Kahanic SP, Forero A, et al. Results of a phase ii study with bendamustine and ofatumumab in untreated indolent B-cell non-Hodgkin's lymphoma [abstract 778]. Blood 2011;118:. [Available online at: http://ash.confex.com/ash/2011/webprogram/Paper37409.html; cited April 20, 2012]
30. Jerkeman M, Kolstad A, Laurell A, et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 years with mantle cell lymphoma: results from the phase i portion of the Nordic Lymphoma Group mcl4 (lena-berit) trial [abstract 2700]. Blood 2011;118:. [Available online at: http://ash.confex.com/ash/2011/webprogram/Paper36728.html; cited April 20, 2012]
31. Visco C, Zambello R, Paolini R, et al. Rituximab, bendamustine and cytarabine (r-bac) is a very active regimen in patients with mantle cell lymphoma not eligible for intensive chemotherapy or autologous transplant [abstract 2677]. Blood 2011;118:. [Available online at: http://ash.confex.com/ash/2011/webprogram/Paper39061.html; cited April 20, 2012]
32. Cheson BD, Friedberg JW, Kahl BS, van der Jagt RH, Tremmel L, Zaks T. Bendamustine produces durable responses with an acceptable long-term safety profile in patients with rituximab-refractory non-Hodgkin's lymphoma: a pooled analysis [abstract 2681]. Blood 2009;114
33. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001;12:725-9.
34. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase ii multicenter, single-agent study. J Clin Oncol 2008;26:204-10.
35. Itoh K, Ando K, Ogura M, et al. Durable responses with bendamustine monotherapy in patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma (b-nhl) and mantle-cell lymphoma (mcl): updated follow-up data from a Japanese multicenter phase ii study [abstract 4884]. Blood 2010;116
36. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2010;116:106-14.
37. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-9.
38. Weide R, Hess G, Köppler H, et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase ii study of the German Low Grade Lymphoma Study Group (glsg). Leuk Lymphoma 2007;48:1299-306.
39. Robinson KS, Williams ME, van der Jagt RH, et al. Phase ii multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473-9.
40. Fowler N, Kahl BS, Rosen P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the Phase 2 vertical study [abstract 933]. Blood 2009;114
41. Friedberg JW, Vose JM, Kelly JL, et al. Bendamustine, bortezomib and rituximab in patients (pts) relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (nhl): a multicenter phase ii clinical trial [abstract 924]. Blood 2009;114
42. Rummel MJ, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas-final results of the randomized phase iii study nhl 2-2003 on behalf of the stil (Study Group Indolent Lymphomas, Germany) [abstract 856]. Blood 2010;116